Volume 132, Issue 1, Pages 66-75 (January 2007) Once-Daily, High-Concentration MMX Mesalamine in Active Ulcerative Colitis Michael A. Kamm, William J. Sandborn, Miguel Gassull, Stefan Schreiber, Lechoslaw Jackowski, Todd Butler, Andrew Lyne, David Stephenson, Mary Palmen, Raymond E. Joseph Gastroenterology Volume 132, Issue 1, Pages 66-75 (January 2007) DOI: 10.1053/j.gastro.2006.10.011 Copyright © 2007 AGA Institute Terms and Conditions
Figure 1 Disposition of patients enrolled in the study. *Two patients were randomized in error and subsequently excluded. One patient had a positive stool culture and was excluded as a screen failure. Neither patient received study treatment. QD, once daily; TID, 3 times daily; AEs, adverse events; SAEs, serious adverse events; ITT, intent-to-treat; PP, per protocol. Gastroenterology 2007 132, 66-75DOI: (10.1053/j.gastro.2006.10.011) Copyright © 2007 AGA Institute Terms and Conditions
Figure 2 Percentage of patients in clinical and endoscopic remission at week 8 (intent-to-treat population, n = 341). **P = .01; ***P = .007. QD, once daily; TID, 3 times per day. Gastroenterology 2007 132, 66-75DOI: (10.1053/j.gastro.2006.10.011) Copyright © 2007 AGA Institute Terms and Conditions